

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866) 217-9197 (toll free).

Reviewer: Durreshwar Anjum

Timestamp: Mon Nov 05 08:26:02 EST 2007

=====

Application No: 10516766 Version No: 2.0

Input Set:

Output Set:

Started: 2007-10-22 09:08:19.004
Finished: 2007-10-22 09:08:20.503
Elapsed: 0 hr(s) 0 min(s) 1 sec(s) 499 ms
Total Warnings: 8
Total Errors: 0
No. of SeqIDs Defined: 41
Actual SeqID Count: 41

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (30)
W 213	Artificial or Unknown found in <213> in SEQ ID (31)
W 213	Artificial or Unknown found in <213> in SEQ ID (32)
W 213	Artificial or Unknown found in <213> in SEQ ID (33)
W 213	Artificial or Unknown found in <213> in SEQ ID (34)
W 213	Artificial or Unknown found in <213> in SEQ ID (35)
W 213	Artificial or Unknown found in <213> in SEQ ID (36)
W 213	Artificial or Unknown found in <213> in SEQ ID (37)

SEQUENCE LISTING

<110> Pastan, Ira H.
Nagata, Satoshi
Onda, Masanori
Numata, Yoshito
Santora, Kenneth
Beers, Richard
Kreitman, Robert
Sinha, Abhishek
The Government of the United States of America
as represented by The Secretary of the
Department of Health and Human Services

<120> Anti-CD30 Stalk and Anti-CD30 Antibodies Suitable for
Use in Immunotoxins

<130> 015280-464200US

<140> 10516766
<141> 2004-12-03

<150> US 60/387,293
<151> 2002-06-07

<150> US 60/411,032
<151> 2002-09-16

<150> WO PCT/US03/18373
<151> 2003-06-09

<160> 41

<170> PatentIn Ver. 2.1

<210> 1
<211> 595
<212> PRT
<213> Homo sapiens

<220>
<223> CD 30 antigen, tumor necrosis factor receptor
superfamily, member 8, isoform 1 precursor
(TNFRSF8), Ki-1 antigen, cytokine receptor CD30,
lymphocyte activation antigen CD30, CD30L receptor

<400> 1
Met Arg Val Leu Leu Ala Ala Leu Gly Leu Leu Phe Leu Gly Ala Leu
1 5 10 15

Arg Ala Phe Pro Gln Asp Arg Pro Phe Glu Asp Thr Cys His Gly Asn
20 25 30

Pro Ser His Tyr Tyr Asp Lys Ala Val Arg Arg Cys Cys Tyr Arg Cys
35 40 45

Pro Met Gly Leu Phe Pro Thr Gln Gln Cys Pro Gln Arg Pro Thr Asp
50 55 60

Cys Arg Lys Gln Cys Glu Pro Asp Tyr Tyr Leu Asp Glu Ala Asp Arg
65 70 75 80

Cys Thr Ala Cys Val Thr Cys Ser Arg Asp Asp Leu Val Glu Lys Thr
85 90 95

Pro Cys Ala Trp Asn Ser Ser Arg Val Cys Glu Cys Arg Pro Gly Met
100 105 110

Phe Cys Ser Thr Ser Ala Val Asn Ser Cys Ala Arg Cys Phe Phe His
115 120 125

Ser Val Cys Pro Ala Gly Met Ile Val Lys Phe Pro Gly Thr Ala Gln
130 135 140

Lys Asn Thr Val Cys Glu Pro Ala Ser Pro Gly Val Ser Pro Ala Cys
145 150 155 160

Ala Ser Pro Glu Asn Cys Lys Glu Pro Ser Ser Gly Thr Ile Pro Gln
165 170 175

Ala Lys Pro Thr Pro Val Ser Pro Ala Thr Ser Ser Ala Ser Thr Met
180 185 190

Pro Val Arg Gly Gly Thr Arg Leu Ala Gln Glu Ala Ala Ser Lys Leu
195 200 205

Thr Arg Ala Pro Asp Ser Pro Ser Ser Val Gly Arg Pro Ser Ser Asp
210 215 220

Pro Gly Leu Ser Pro Thr Gln Pro Cys Pro Glu Gly Ser Gly Asp Cys
225 230 235 240

Arg Lys Gln Cys Glu Pro Asp Tyr Tyr Leu Asp Glu Ala Gly Arg Cys
245 250 255

Thr Ala Cys Val Ser Cys Ser Arg Asp Asp Leu Val Glu Lys Thr Pro
260 265 270

Cys Ala Trp Asn Ser Ser Arg Thr Cys Glu Cys Arg Pro Gly Met Ile
275 280 285

Cys Ala Thr Ser Ala Thr Asn Ser Cys Ala Arg Cys Val Pro Tyr Pro
290 295 300

Ile Cys Ala Ala Glu Thr Val Thr Lys Pro Gln Asp Met Ala Glu Lys
305 310 315 320

Asp Thr Thr Phe Glu Ala Pro Pro Leu Gly Thr Gln Pro Asp Cys Asn
325 330 335

Pro Thr Pro Glu Asn Gly Glu Ala Pro Ala Ser Thr Ser Pro Thr Gln
340 345 350

Ser Leu Leu Val Asp Ser Gln Ala Ser Lys Thr Leu Pro Ile Pro Thr
355 360 365

Ser Ala Pro Val Ala Leu Ser Ser Thr Gly Lys Pro Val Leu Asp Ala
370 375 380

Gly Pro Val Leu Phe Trp Val Ile Leu Val Leu Val Val Val Gly
385 390 395 400

Ser Ser Ala Phe Leu Leu Cys His Arg Arg Ala Cys Arg Lys Arg Ile
405 410 415

Arg Gln Lys Leu His Leu Cys Tyr Pro Val Gln Thr Ser Gln Pro Lys
420 425 430

Leu Glu Leu Val Asp Ser Arg Pro Arg Arg Ser Ser Thr Gln Leu Arg
435 440 445

Ser Gly Ala Ser Val Thr Glu Pro Val Ala Glu Glu Arg Gly Leu Met
450 455 460

Ser Gln Pro Leu Met Glu Thr Cys His Ser Val Gly Ala Ala Tyr Leu
465 470 475 480

Glu Ser Leu Pro Leu Gln Asp Ala Ser Pro Ala Gly Gly Pro Ser Ser
485 490 495

Pro Arg Asp Leu Pro Glu Pro Arg Val Ser Thr Glu His Thr Asn Asn
500 505 510

Lys Ile Glu Lys Ile Tyr Ile Met Lys Ala Asp Thr Val Ile Val Gly
515 520 525

Thr Val Lys Ala Glu Leu Pro Glu Gly Arg Gly Leu Ala Gly Pro Ala
530 535 540

Glu Pro Glu Leu Glu Glu Leu Glu Ala Asp His Thr Pro His Tyr
545 550 555 560

Pro Glu Gln Glu Thr Glu Pro Pro Leu Gly Ser Cys Ser Asp Val Met
565 570 575

Leu Ser Val Glu Glu Gly Lys Glu Asp Pro Leu Pro Thr Ala Ala
580 585 590

Ser Gly Lys
595

<210> 2
<211> 118
<212> PRT
<213> Mus musculus

<220>
<223> heavy chain variable region (VH) of anti-CD30
monoclonal antibody (MAb) T6

<400> 2
Gln Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Thr Pro Ser Gln
1 5 10 15

Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Ser Lys Tyr
20 25 30

Ser Ile His Trp Val Arg Gln Pro Pro Gly Arg Gly Leu Glu Trp Leu
35 40 45

Gly Met Ile Trp Gly Val Glu Asn Thr Asp Tyr Asn Ser Ala Leu Lys
50 55 60

Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu
65 70 75 80

Lys Met Asn Ser Leu Gln Ser Asp Asp Thr Ala Met Tyr Tyr Cys Ala
85 90 95

Arg Lys Asp Leu Gly Leu Tyr Gly Met Asn Tyr Trp Gly Gln Gly Ile
100 105 110

Ser Val Thr Val Ser Ala
115

<210> 3
<211> 120
<212> PRT
<213> Mus musculus

<220>
<223> heavy chain variable region (VH) of anti-CD30
monoclonal antibody (MAb) T7

<400> 3
Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Ser
1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Tyr
20 25 30

Trp Met Asn Trp Met Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Gln Ile Tyr Pro Gly Asp Asp Asp Thr Asn Tyr Asn Gly Lys Phe
50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
85 90 95

Ala Arg Arg Glu Thr Gly Arg Gly Ala Trp Phe Thr Tyr Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ala
115 120

<210> 4
<211> 120
<212> PRT
<213> Mus musculus

<220>
<223> heavy chain variable region (VH) of anti-CD30
monoclonal antibody (MAb) T13

<400> 4
Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr
20 25 30

Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Ser Thr Gly Tyr Thr Asp Tyr Asn Glu Lys Phe
50 55 60

Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Val Arg Arg Gly Ser Tyr Asp Gly Asn Pro Phe Ala Tyr Trp Gly Gln
100 105 110

Gly Thr Leu Val Ser Val Ser Ala
115 120

<210> 5
<211> 117
<212> PRT
<213> Mus musculus

<220>
<223> heavy chain variable region (VH) of anti-CD30
monoclonal antibody (MAb) T14

<400> 5
Glu Val Gln Leu Val Glu Ser Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15

Ser Leu Lys Leu Ser Cys Gly Val Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30

Tyr Met Tyr Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val

35

40

45

Ala Ser Ile Ser Ser Gly Gly Ser Tyr Thr Tyr Tyr Ser Asp Ser Val

50

55

60

Lys Gly Arg Leu Thr Ile Ser Arg Asp Asn Thr Lys Asn Asn Leu Tyr

65

70

75

80

Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys

85

90

95

Val Arg Gly Pro Gly Gly Val Leu Asp Tyr Trp Gly Gln Gly Thr Thr

100

105

110

Leu Thr Val Ser Ser

115

<210> 6

<211> 119

<212> PRT

<213> Mus musculus

<220>

<223> heavy chain variable region (VH) of anti-CD30
monoclonal antibody (MAb) T24

<400> 6

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Arg Pro Gly Ala

1

5

10

15

Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Ser Tyr

20

25

30

Trp Ile Asp Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile

35

40

45

Gly Asn Ile Tyr Pro Ser Asn Ala Tyr Thr Asn Tyr Asn Gln Lys Phe

50

55

60

Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr

65

70

75

80

Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys

85

90

95

Thr Ser Val Leu Asp Tyr Phe Tyr Ala Met Asp Tyr Trp Gly Gln Gly

100

105

110

Thr Ser Val Thr Val Ser Ser

115

<210> 7

<211> 118

<212> PRT

<213> Mus musculus

<220>

<223> heavy chain variable region (VH) of anti-CD30
monoclonal antibody (MAb) T25

<400> 7

Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln
1 5 10 15

Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Asn Thr Ser
20 25 30

Gly Val Gly Val Gly Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu
35 40 45

Trp Leu Ala His Ile Trp Trp Asp Asp Asp Glu Arg Tyr Asn Pro Val
50 55 60

Leu Lys Ser Arg Leu Thr Ile Ser Lys Asp Thr Ser Ser Asn Gln Val
65 70 75 80

Phe Leu Lys Ile Ala Asn Val Asp Thr Ala Asp Ser Ala Thr Tyr Tyr
85 90 95

Cys Val Arg Ser Met Val Ala Trp Phe Pro Tyr Trp Gly Arg Gly Thr
100 105 110

Leu Val Thr Val Ser Ala

115

<210> 8

<211> 125

<212> PRT

<213> Mus musculus

<220>

<223> heavy chain variable region (VH) of anti-CD30
monoclonal antibody (MAb) control HeFi-I

<400> 8

Glu Val Lys Leu Val Glu Ser Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Asp Tyr
20 25 30

Tyr Met Asn Trp Val Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu
35 40 45

Gly Phe Ile Arg Asn Lys Ala Asn Gly Tyr Thr Thr Glu Phe Ser Ala
50 55 60

Ser Val Met Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Gln Ser Ile
65 70 75 80

Leu Tyr Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Ser Ala Thr Tyr

85 90 95

Tyr Cys Ala Arg Asp Pro Pro Tyr Gly Asn Pro His Tyr Tyr Ala Met
100 105 110

Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
115 120 125

<210> 9
<211> 121
<212> PRT
<213> Mus musculus

<220>
<223> heavy chain variable region (VH) of anti-CD30
monoclonal antibody (MAb) CL2

<400> 9
Glu Val Gln Leu Lys Gln Ser Gly Thr Glu Leu Val Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30

Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Asn Ile Asn Pro Ser Asn Gly Gly Thr Asn Tyr Asn Glu Lys Phe
50 55 60

Lys Ser Lys Ala Thr Leu Thr Ile Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Arg Thr Glu Thr Ala Gln Ala Ser Pro Phe Ala Tyr Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 10
<211> 120
<212> PRT
<213> Mus musculus

<220>
<223> heavy chain variable region (VH) of anti-CD30
monoclonal antibody (MAb) Ki-4

<400> 10
Gln Val Lys Leu Gln Glu Ser Gly Thr Glu Leu Ala Lys Pro Gly Ala
1 5 10 15

Ala Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Asn Thr Ala Tyr Thr Asp Tyr Asn Gln Lys Phe
50 55 60

Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Lys Lys Thr Thr Gln Thr Trp Gly Phe Pro Phe Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 11
<211> 120
<212> PRT
<213> Mus musculus

<220>
<223> heavy chain variable region (VH) of anti-CD30
monoclonal antibody (MAb) T420

<400> 11

Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Ala Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
20 25 30

Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Asp Leu Glu Trp Ile
35 40 45

Gly Tyr Ile Asn Pro Ser Thr Asp Tyr Thr Asp Tyr Asn Gln Lys Phe
50 55 60

Lys Asp Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Thr Arg His Tyr Gly Ser Ser Tyr Gly Phe Ala Tyr Trp Gly Gln
100 105 110

Gly Thr Leu Val Thr Val Ser Ala
115 120

<210> 12

<211> 119

<212> PRT